BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Roche (RHHBY)'s Good Cholesterol Drug Shows Negative Side Effects


11/6/2012 6:59:40 AM

Roche Holding AG (ROG)’s abandoned heart drug dalcetrapib, designed to raise levels of good cholesterol, also boosted blood pressure and inflammation, researchers said. Dalcetrapib marks the second failure in what was expected to be a new blockbuster class of heart medicines known as CETP inhibitors. The Basel, Switzerland-based drugmaker halted development of the drug in May, saying an early look at study results found the medicine wasn’t helping patients. Pfizer Inc. (PFE) dropped its pill torcetrapib in December 2006 after studies showed it raised blood pressure and boosted death rates. The findings presented today at the American Heart Association meeting in Los Angeles showed dalcetrapib had unexpected side effects that may have contributed to its downfall. While it didn’t increase hypertension in the same manner or amount as torcetrapib and there weren’t more deaths, it’s possible the medicines could have damaged blood vessels, the researchers said. That may have implications for Merck & Co. (MRK) and Eli Lilly & Co. (LLY), who are developing similar compounds.

Read at BusinessWeek
Read at News Release

Roche
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES